Acticor Biotech, SAS
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Acticor Biotech, SAS
Private Company Edition: VC deals are surging this year for cell and gene therapy firms, according to ARM’s third quarter report. Also, Vivo Capital and the CF Foundation plan to invest nearly $2bn in health care and life science opportunities, and Akeso completes $150m series D.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced September and October 2018.
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.
The latest biopharma industry appointments include new CEOs at Neurotrope, Lannett, Amneal and Peregrine Pharmaceuticals, a new CFO at Concert Pharmaceuticals, a new EVP of global operations at Allergan, a new CMO at Acticor, and a US country manager for Alliance Pharma.
- Antisense, Oligonucleotides
- Large Molecule